iSpecimen Inc. Increase (Decrease) in Deferred Revenue
iSpecimen Inc. (ISPC) reported Increase (Decrease) in Deferred Revenue of -$132.20 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2024-11-07
- iSpecimen Inc. increase (decrease) in deferred revenue for the quarter ending 2024-09-30 was $24.70K.
- iSpecimen Inc. increase (decrease) in deferred revenue for the quarter ending 2024-06-30 was -$13.81K.
- iSpecimen Inc. increase (decrease) in deferred revenue for the quarter ending 2024-03-31 was -$143.09K.
- iSpecimen Inc. increase (decrease) in deferred revenue for the quarter ending 2023-12-31 was $368.86K, a 178.73% increase year-over-year.
- iSpecimen Inc. increase (decrease) in deferred revenue for fiscal 2023 was $283.44K.
- iSpecimen Inc. increase (decrease) in deferred revenue for fiscal 2022 was -$522.41K.
- iSpecimen Inc. increase (decrease) in deferred revenue for fiscal 2021 was -$218.51K, a 125.02% decline from fiscal 2020.
- iSpecimen Inc. increase (decrease) in deferred revenue for fiscal 2020 was $873.25K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 9 month as first filed | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|---|
| 2024-09-30 | $24.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $10.89K derived: sum of 2 quarters · filed 2024-11-07 | -$132.20K 10-Q · filed 2024-11-07 | $236.66K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-06-30 | -$13.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$156.90K 10-Q · filed 2024-08-06 | $211.96K derived: sum of 3 quarters · filed 2024-08-06 | $169.27K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-03-31 | -$143.09K 10-Q · filed 2024-05-07 | $225.77K derived: sum of 2 quarters · filed 2024-05-07 | $183.08K derived: sum of 3 quarters · filed 2024-11-07 | $175.03K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-12-31 | $368.86K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $326.17K derived: sum of 2 quarters · filed 2024-11-07 | $318.12K derived: sum of 3 quarters · filed 2024-11-07 | $283.44K 10-K · filed 2024-03-13 | |
| 2023-09-30 | -$42.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$50.74K derived: sum of 2 quarters · filed 2024-11-07 | -$85.42K 10-Q · filed 2024-11-07 | $46.91K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$8.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$42.73K 10-Q · filed 2024-08-06 | $89.60K derived: sum of 3 quarters · filed 2024-08-06 | -$245.38K derived: sum of 4 quarters · filed 2024-08-06 | |
| 2023-03-31 | -$34.68K 10-Q · filed 2024-05-07 | $97.65K derived: sum of 2 quarters · filed 2024-05-07 | -$237.32K derived: sum of 3 quarters · filed 2024-05-07 | -$469.67K derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | $132.33K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$202.65K derived: sum of 2 quarters · filed 2024-03-13 | -$434.99K derived: sum of 3 quarters · filed 2024-03-13 | -$522.41K 10-K · filed 2024-03-13 | |
| 2022-09-30 | -$334.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$567.32K derived: sum of 2 quarters · filed 2023-11-02 | -$654.75K 10-Q · filed 2023-11-02 | -$654.75K 10-Q · filed 2022-11-08 | -$718.72K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$232.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$319.77K 10-Q · filed 2023-08-02 | -$383.74K derived: sum of 3 quarters · filed 2023-08-02 | -$467.88K derived: sum of 4 quarters · filed 2023-08-02 | |
| 2022-03-31 | -$87.42K 10-Q · filed 2023-05-04 | -$151.40K derived: sum of 2 quarters · filed 2023-05-04 | -$235.54K derived: sum of 3 quarters · filed 2023-05-04 | -$236.74K derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | -$63.98K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-30 | -$148.11K derived: sum of 2 quarters · filed 2023-03-30 | -$149.32K derived: sum of 3 quarters · filed 2023-03-30 | -$218.51K 10-K/A · filed 2023-03-30 | |
| 2021-09-30 | -$84.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$85.34K derived: sum of 2 quarters · filed 2022-11-08 | -$154.53K 10-Q · filed 2022-11-08 | $136.81K derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | -$1.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$70.39K 10-Q · filed 2022-08-04 | $220.95K derived: sum of 3 quarters · filed 2022-08-04 | $443.69K derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$69.19K 10-Q · filed 2022-05-10 | $222.15K derived: sum of 2 quarters · filed 2022-05-10 | $444.89K derived: sum of 3 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $291.34K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $514.08K derived: sum of 2 quarters · filed 2022-03-22 | $873.25K 10-K · filed 2022-03-22 | ||
| 2020-09-30 | $222.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $581.91K 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $359.17K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |